Zepbound and Mounjaro Cost Without Insurance: What You'll Actually Pay

Zepbound and Mounjaro are the same medication — tirzepatide — sold under two brand names, and that single fact is the key to their cost without insurance. Mounjaro is FDA-approved for type 2 diabetes; Zepbound is approved for chronic weight management. The list price of each runs above $1,000 a month, but almost no uninsured patient pays that. Through Eli Lilly's LillyDirect self-pay programme, Zepbound single-dose vials start around $399 a month, and a manufacturer savings card can cut commercially insured costs further. The catch worth saying up front: the cheapest tirzepatide offers are often compounded or grey-market, and cheapest is not the same as safest.

This guide maps every real route to a lower tirzepatide price — insurance, manufacturer self-pay, savings cards, discount cards, patient assistance, and compounded versions — what each costs, who it fits, and how to tell a fair price from an unsafe one. It is the tirzepatide companion to our broader guide to lowering the cost of GLP-1 medications, and the brand-level partner to our Ozempic and Wegovy cost pages.

One molecule, two brands — and why that decides your price

Tirzepatide is a single active ingredient that Eli Lilly markets under two names for two different approved uses. Mounjaro came first, approved in 2022 for type 2 diabetes. Zepbound followed in late 2023, approved for chronic weight management in adults with obesity or overweight plus a weight-related condition. The molecule, the dosing schedule, and the once-weekly injection are the same; what differs is the indication on the label — and in the U.S. payment system, indication is what drives coverage, savings-card eligibility, and which assistance programmes apply. We compare the two brands in detail in Mounjaro vs Zepbound, and the mechanism they share in how tirzepatide works.

Why does the same drug carry two names at all? Because U.S. drug approval is indication-specific, and insurers treat a diabetes drug and a weight-loss drug very differently. A plan that readily covers Mounjaro for a diabetes diagnosis may flatly exclude Zepbound for weight management — even though the syringe contents are identical. That split is the spine of everything below, and it is the same dynamic we unpack in GLP-1 use for weight loss vs diabetes.

	Mounjaro	Zepbound
Active ingredient	Tirzepatide	Tirzepatide (same molecule)
FDA-approved use	Type 2 diabetes	Chronic weight management (obesity / overweight + comorbidity)
Approx. list price / month	~$1,069	~$1,086
Manufacturer self-pay	No dedicated cash-vial programme	LillyDirect single-dose vials from ~$399/month
Savings card	Commercial insurance, diabetes indication	Up to ~$469/month off for the commercially insured
Who it tends to fit	People with a type 2 diabetes diagnosis	People treating obesity without diabetes

Prices throughout this guide are approximate, change frequently, and should be verified against Lilly or the dispensing pharmacy directly before you rely on them.

The list price almost nobody pays

The wholesale list price anchors a system most patients never touch directly. As of early 2026, Zepbound's 28-day list price sits around $1,086 and Mounjaro's around $1,069 — figures that appear on insurance paperwork and in policy debates far more often than on patient receipts. What an uninsured patient actually pays is a layered landscape: the list price is the ceiling, and the floor depends on which programmes you qualify for and how much logistical workflow you are willing to manage.

The single most important reason the two brands diverge in real-world cost is that Lilly built a dedicated cash-pay channel for Zepbound — but not, in the same form, for Mounjaro. For weight-management patients without coverage, that channel is usually the cheapest predictable branded price. For diabetes patients, the route to a low price runs more often through insurance and the Mounjaro savings card. The rest of this guide follows those two paths.

Every realistic route to pay less for tirzepatide

There is no single "cheapest" answer — the right route depends on whether you have insurance, which brand you need, and your tolerance for paperwork. Here is the full menu, with the trade-offs that matter.

Route	Typical monthly cost	Who it fits	Key caveat
Insurance (covered)	$0–$100 copay	Plans covering tirzepatide for your indication	Diabetes covered more often than weight; expect prior authorization
LillyDirect self-pay vials (Zepbound)	From ~$399	Uninsured weight-management patients	Self-injected vials with a syringe, not auto-injector pens
Manufacturer savings card	Up to ~$469 off (Zepbound)	Commercial insurance that excludes the drug	Barred for Medicare/Medicaid by federal rules
Pharmacy discount card (GoodRx, SingleCare)	Varies by pharmacy and dose	Cash payers at retail pharmacies	Not insurance; doesn't stack with it
Patient assistance program	$0 if eligible	Low-income, uninsured patients	Strict income limits; leans toward diabetes
Compounded tirzepatide	Lower, but variable	Specific clinical justifications only	Legally narrowed since tirzepatide left shortage status; quality varies

Use insurance first — and appeal a denial

If any route reaches a copay, it is insurance. The obstacle is the indication split: many plans cover Mounjaro for diagnosed type 2 diabetes while excluding Zepbound for weight management. A denial is not the end of the road — the appeal and prior-authorization process succeeds more often than people expect. We lay out the procedural playbook in getting a GLP-1 covered by insurance and prior authorization tips. Because coverage hinges on indication, confirming which use your prescription is written for — and whether you even qualify for a tirzepatide prescription in the first place — is the cheapest move you can make before paying cash.

LillyDirect self-pay vials (the most predictable cash price for Zepbound)

Eli Lilly's LillyDirect Self Pay programme offers Zepbound as single-dose vials, with the lowest dose starting around $399 a month and higher doses priced in tiers above that. The vials bypass the pharmacy-benefit-manager chain, which is how the cash price comes in far below the roughly $1,086 list. The trade-off is format: you draw the dose from a vial with a syringe and self-inject, rather than using the auto-injector pen. For many patients that is a minor adjustment for a substantial saving; for the needle-averse it is worth weighing.

The path is straightforward: obtain a valid prescription from your own clinician or a telehealth provider, then route it to LillyDirect's pharmacy rather than a retail counter. You pay the fixed cash price directly and the medication ships to you — no rebate games, no insurance negotiation. There is no equivalent dedicated cash-vial programme for Mounjaro, so diabetes patients without coverage generally lean on the savings card, discount cards, or assistance instead.

Manufacturer savings cards (for the commercially insured)

If you have commercial insurance that simply excludes tirzepatide, the manufacturer savings card is often the cheapest path. The Zepbound savings card has offered up to roughly $469 a month off for commercially insured patients whose plans don't cover the drug, with a lower out-of-pocket cost for those whose plans do. Lilly runs a comparable card for Mounjaro on the diabetes side. Both cards exclude Medicare, Medicaid, and other government programmes — a federal anti-kickback rule, not a manufacturer choice — which is precisely the gap the self-pay vials fill for uninsured Zepbound patients.

Pharmacy discount cards

Discount platforms such as GoodRx and SingleCare negotiate cash prices that can undercut the pharmacy counter, with the figure varying by pharmacy, brand, and dose. These are not insurance and do not stack with it, but for a cash payer — particularly a Mounjaro patient without a dedicated self-pay vial option — they are worth comparing against every other route before you fill. Always price your specific dose at more than one pharmacy; the spread can be wide.

Patient assistance programmes

Lilly runs a patient assistance programme that can provide tirzepatide at no cost to low-income, uninsured patients who meet eligibility criteria. The income limits are strict and the programme leans toward diabetes indications, but for those who qualify this is the genuinely cheapest legitimate route — free. Applying typically means submitting proof of income, evidence that you are uninsured or that your plan excludes the drug, and a prescriber's sign-off; approvals are time-limited and must be renewed. It is paperwork-heavy and slower than a self-pay checkout, so it suits patients who can plan ahead rather than those who need medication this week.

Compounded tirzepatide (cheaper, but the rules — and risks — changed)

During the 2023–2024 shortage, compounding pharmacies could legally produce tirzepatide, often at a noticeably lower price than branded vials. Once the FDA removed tirzepatide from its shortage list in late 2024, the legal grounds for routine compounding narrowed sharply. Compounded tirzepatide remains available through some telehealth channels under specific clinical justifications, but this is no longer the open market it was during the shortage. If you are weighing this route, read compounded vs branded GLP-1s first, and the safety section below — the cheapest tirzepatide offers online are frequently the riskiest.

"Cheapest" isn't always safest — how to vet a low price

This is the part most price-comparison pages skip. The lowest advertised prices for tirzepatide frequently come from sources operating in legal grey areas — unregulated "research" peptides, overseas sellers, or compounders cutting corners. The FDA has repeatedly warned about counterfeit and improperly compounded GLP-1 products, including incorrect dosing and unverified active ingredients. A bargain that arrives as the wrong molecule, the wrong dose, or with no medical oversight is not a saving — it is a health risk wearing a discount sticker.

Before you trust a low tirzepatide price, confirm:

• A real prescription and a real clinician. A legitimate provider evaluates you before prescribing — not a checkout page that ships after a one-line form.
• A named, credentialed pharmacy. For compounded products, ask whether it is a 503A (state-licensed) or 503B (FDA-registered outsourcing) pharmacy, and what testing the active ingredient underwent.
• No "research only" or "not for human use" labelling. That phrasing is a hard stop — those products are not made or regulated as medicines.
• Transparent sourcing. Avoid any seller who won't say where the drug is made or who won't connect you to a licensed prescriber.

By contrast, a safe, legitimate purchase has a recognisable shape: a licensed clinician who evaluates you and is reachable for follow-up; an FDA-approved product (or, for compounding, a named 503A/503B pharmacy with tested ingredients); medication shipped cold-chain where required and clearly labelled with dose and lot number; and pricing you can trace to Lilly's own programmes, a real pharmacy, or a transparent telehealth service. For a fuller comparison of legitimate telehealth providers on price, sourcing, and clinical quality, see our review of telehealth GLP-1 prescription services.

Is tirzepatide worth the cost? What you're paying for

Cost only makes sense against value. In SURMOUNT-1, the pivotal randomised trial of tirzepatide for obesity, participants without diabetes lost up to about 20.9% of body weight over 72 weeks at the highest dose — among the largest average reductions ever recorded with a weight-management medication, and a result that approaches the range of some bariatric surgery. For comparison, semaglutide produced about 14.9% mean weight loss over 68 weeks in the STEP 1 trial. That efficacy is the core of what the price buys.

Two facts shape the cost calculation, though. First, the effect largely depends on continued use — the underlying appetite biology is unchanged when the drug stops, so for many people this is an ongoing cost rather than a one-off purchase. Second, tirzepatide is a prescription medicine for specific indications, not a casual buy. Understanding the mechanism behind the price — set out in our complete guide to GLP-1 medications — helps you judge whether a given route is a fair deal. One way to frame it: at a self-pay price near $399–$549 a month, a person achieving 15–20% weight loss is paying for a clinically meaningful health change that diet and exercise alone rarely sustain at that magnitude. At an unregulated grey-market "deal" with no oversight, the apparent saving evaporates the moment the product is mis-dosed or counterfeit.

How the cost adds up over time

A monthly price is only part of the picture, because tirzepatide treatment is ongoing, not a one-time event. You start on a low dose and step up over several months to limit side effects, paying each month during the climb — often before you see the full effect. The maintenance dose you eventually settle on determines your steady-state cost. Because much of the lost weight tends to return after stopping, planning for a long-term cost is part of an honest budget. Factoring in titration and maintenance, a realistic annual figure on the LillyDirect self-pay vials lands roughly in the $5,000–$6,500 range — well below list, but not trivial, and worth weighing before you start rather than after.

A quick decision rule: if you have coverage, use it and appeal any denial; if you don't and you need Zepbound for weight management, the LillyDirect self-pay vials are usually the cheapest predictable branded price; if you need Mounjaro for diabetes without coverage, compare the savings card, discount cards, and patient assistance; and only consider compounded tirzepatide through a credentialed, clinician-led provider. For the full cross-drug version of this playbook — including the semaglutide brands — return to the GLP-1 cost hub or browse the wider GLP-1 science hub.

Common mistakes that quietly cost tirzepatide patients more

The difference between a fair price and an inflated one is often a handful of avoidable errors:

• Paying the retail counter price without checking alternatives. The walk-in cash price is frequently the worst available — compare the LillyDirect self-pay vials and a discount card for your exact brand and dose first.
• Assuming the two brands are interchangeable on your plan. A plan may cover Mounjaro for diabetes and exclude Zepbound for weight management; knowing which indication your prescription is written for tells you which programmes you can actually use.
• Accepting an insurance denial as final. Many denials are overturned on appeal or with a stronger prior-authorization submission; giving up forfeits the cheapest possible outcome.
• Overlooking the vial-versus-pen trade. The LillyDirect self-pay vials are markedly cheaper than the auto-injector format; if you're comfortable drawing a dose with a syringe, that single choice can sharply cut your monthly cost.
• Chasing the lowest grey-market price. Unregulated peptides and overseas sellers can cost more in the end — wasted money on a product that's wrong, plus the health risk that comes with it.
• Not re-checking prices. Programmes and discount rates change often in this market; a route that was cheapest six months ago may not be today.

Key takeaways

• Zepbound and Mounjaro are the same drug, tirzepatide; Mounjaro is approved for type 2 diabetes and Zepbound for chronic weight management, and that split drives coverage and pricing.
• List prices stay above $1,000/month (~$1,086 Zepbound, ~$1,069 Mounjaro), but almost no uninsured patient pays that.
• For uninsured weight-management patients, LillyDirect self-pay Zepbound vials from about $399/month are usually the cheapest predictable branded price.
• With commercial insurance that excludes the drug, a manufacturer savings card is often cheapest (up to ~$469/month off for Zepbound); these exclude Medicare and Medicaid.
• Discount cards and patient assistance are worth comparing — assistance can be free if you qualify, and matters most for Mounjaro, which has no dedicated cash-vial programme.
• Compounded tirzepatide is cheaper but legally narrowed since the shortage ended; insist on a real prescription, a credentialed 503A/503B pharmacy, and verified sourcing. Cheapest is only a deal if it's safe.

Want clear, unbiased GLP-1 guidance — without the sales pitch? Modern Weight Science is independent and evidence-based. Subscribe to our free weekly newsletter for plain-English updates on cost, access, and the science — no spam, no product pitches, no affiliate links.